Welcome to our dedicated page for nyse news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on nyse stock.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is a pioneering biopharmaceutical company focused on developing targeted radiotherapies for treating cancer. Founded with the mission of improving survival outcomes for patients with difficult-to-treat cancers, Actinium leverages its proprietary Antibody Radiation Conjugates (ARCs) to deliver potent radiation directly to cancer cells while sparing healthy tissue.
Actinium's leading candidates include Iomab-B and Actimab-A. Iomab-B is a radioimmunotherapy intended for conditioning before bone marrow transplants in patients with active relapsed or refractory acute myeloid leukemia (r/r AML). The pivotal Phase 3 SIERRA trial has demonstrated Iomab-B's ability to significantly improve overall survival and remission rates, particularly in patients with the high-risk TP53 mutation. Advanced filings for Biologics License Application (BLA) and Marketing Authorization Application (MAA) are underway.
Actimab-A, targeting CD33, is being developed as a therapeutic for r/r AML and is currently progressing under the National Cancer Institute’s CRADA pivotal development path. This candidate, along with Iomab-B, has shown promising results in overcoming genetic mutations and providing high response rates.
In addition to its robust pipeline, Actinium is actively involved in partnerships to extend its technology platform to solid tumors. Notable collaborations include those with Astellas Pharma, AVEO Oncology, and LG Chem Life Sciences. The company holds an extensive intellectual property portfolio with over 230 patents and patent applications.
Recent developments include the initiation of a clinical trial for Iomab-ACT, a next-generation conditioning agent for cell and gene therapies such as CAR T-cell therapy. This trial, led by the University of Texas Southwestern Medical Center, aims to replace traditional chemotherapy conditioning with targeted radiotherapy to reduce toxicities and improve patient outcomes.
Actinium’s strong presence at major scientific conferences such as the American Society of Hematology (ASH), European Bone Marrow Transplant Society (EBMT), and Tandem Meetings of ASTCT and CIBMTR underscores its commitment to advancing targeted radiotherapies and highlights the potential of its innovative treatments in transforming cancer care.
Puxin Limited (NYSE: NEW) reported its Q1 2021 financial results, showing a net revenue decline of 8.6% to RMB686.8 million (US$104.8 million) compared to Q1 2020. However, operating income rose 78.9% to RMB6.5 million (US$1.0 million). The company transitioned some learning centers online due to pandemic measures, contributing to a 7.1% drop in student enrollments to 539,355. Despite challenges, net income improved to RMB37.8 million (US$5.8 million), a positive shift from a net loss of RMB43.5 million in Q1 2020. Puxin anticipates Q2 revenues between RMB661.2 million and RMB691.3 million.
First BanCorp. (NYSE: FBP) has announced the declaration of monthly cash dividends on its Series A through E Noncumulative Perpetual Monthly Income Preferred Stock. The dividends are as follows: Series A - $0.14843750 per share, Series B - $0.17395800, Series C - $0.15416670, Series D - $0.15104167, and Series E - $0.14583330. Record dates for Series A to D are December 15, 2020, and Series E on December 15, 2020, with all payments scheduled for December 31, 2020.
First BanCorp. (NYSE: FBP) has declared monthly cash dividends on its Series A through E Noncumulative Perpetual Monthly Income Preferred Stock. The dividends are as follows: Series A at $0.1484, Series B at $0.1740, Series C at $0.1542, Series D at $0.1510, and Series E at $0.1458 per share. The record dates for these dividends range from November 15 to November 25, 2020, with all payments scheduled for November 30, 2020. This reflects the corporation's ongoing commitment to returning value to shareholders.
First BanCorp. (NYSE: FBP) has declared a quarterly cash dividend of $0.05 per share on its common stock. The dividend is payable on December 11, 2020, to shareholders on record as of November 27, 2020. This announcement reflects the corporation's ongoing ability to reward shareholders despite market fluctuations. Notably, First BanCorp. operates across Puerto Rico, the U.S. and British Virgin Islands, and Florida via its subsidiary, FirstBank Puerto Rico.
First BanCorp. (NYSE: FBP) reported net income of $28.6 million ($0.13 per diluted share) for Q3 2020, an increase from $21.3 million in Q2 2020 but a decrease from $46.3 million in Q3 2019. The results included a provision for credit losses of $46.9 million, largely due to the acquisition of BSPR, finalized on September 1, 2020. The acquisition added $5.6 billion in total assets, including $2.6 billion in loans and $4.2 billion in deposits. Net interest income rose to $148.7 million, driven by increased loan balances, while non-interest income totaled $29.9 million.
First BanCorp (NYSE: FBP) has announced it will report its third-quarter financial results for the period ending September 30, 2020, before market open on October 30, 2020. The bank holding company will host a conference call and live webcast to discuss these results at 10:00 a.m. ET on the same day. The call will be accessible via their website, and a replay will be available until October 30, 2021. First BanCorp operates primarily through FirstBank Puerto Rico, providing banking services across Puerto Rico and parts of the U.S.
First BanCorp. (NYSE: FBP) has declared monthly cash dividends for its Series A through E Noncumulative Perpetual Monthly Income Preferred Stock. The dividends are as follows:
- Series A: $0.14843750 per share, 197,386 shares, Record: Oct 29, 2020, Payment: Nov 2, 2020
- Series B: $0.17395800 per share, 296,146 shares, Record: Oct 15, 2020, Payment: Nov 2, 2020
- Series C: $0.15416670 per share, 249,852 shares, Record: Oct 15, 2020, Payment: Nov 2, 2020
- Series D: $0.15104167 per share, 285,522 shares, Record: Oct 15, 2020, Payment: Nov 2, 2020
- Series E: $0.14583330 per share, 415,240 shares, Record: Oct 15, 2020, Payment: Nov 2, 2020
SFL Corporation Ltd. (NYSE: SFL) owns three drilling rigs leased to Seadrill subsidiaries. Seadrill has initiated forbearance agreements with creditors due to missed interest payments in September 2020, allowing time for balance sheet restructuring. Although Seadrill has paid the charter hire for September, the non-payment constitutes an event of default that could enforce cross-default provisions under SFL's leasing agreements. Despite challenges, SFL maintains dialogue with Seadrill and banks to seek solutions.
SFL Corporation Ltd. held its 2020 Annual General Meeting on August 31, where key resolutions were approved. These included setting the maximum number of directors at eight, re-electing existing directors, and increasing the authorized share capital from US$2,000,000 to US$3,000,000. The shareholders approved a remuneration package for the Board of Directors, totaling US$800,000 for the fiscal year. The company has maintained a consistent dividend payout since its NYSE listing in 2004, with a fleet of over 80 vessels across various sectors.
SFL Corporation Ltd. reported its preliminary Q2 2020 results, declaring a quarterly cash dividend of $0.25 per share, marking the 66th consecutive quarterly dividend. The company achieved operating revenue of $118 million and net income of $12 million, despite $15.8 million in negative adjustments. Charter hire collected was approximately $158 million, with a charter backlog increase of $95 million. The dividend will be paid on or around September 30, 2020, to shareholders on record as of September 17.
FAQ
What is Actinium Pharmaceuticals' primary focus?
What is Iomab-B?
What recent achievements has Actinium Pharmaceuticals made?
Who are Actinium Pharmaceuticals' key partners?
What is Actimab-A?
What are the key results from the SIERRA trial?
What is the significance of Actinium's technology platform?
How many patents does Actinium Pharmaceuticals hold?
What is the purpose of Iomab-ACT?
Where can I find more information about Actinium Pharmaceuticals?
